Mar 20th 2013 - Edison Investment Research today published a report on Newron entitled "An Important Year Ahead". In summary, the report says:
Detailed safinamide Phase III Parkinson’s disease (PD) data presented at AAN (American Academy of Neurology) are broadly similar to prior Phase III data and should support regulatory filings, which are anticipated in Q413. Newron and partner Zambon are currently seeking to sub-license safinamide in key regions including the US. Updates on this process and the regulatory filings will be key for the valuation in the next 12 months.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »